Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: Role of the mTORC1/2 and hypoxia-inducible factor pathways

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Selvarajah, J ^a   Nathawat, K ^a   Moumen, A ^a   Ashcroft, M ^b   Carroll, V A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Endothelin 1; HIF 1a; HIF 2a; MTORC1 2; P53; Renal cell carcinoma

Indexed keywords

APIGENIN; ATM PROTEIN; CYCLIN D1; ENDOTHELIN 1; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; DNA DAMAGE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MESSENGER RNA SYNTHESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; UPREGULATION;

APIGENIN; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAMPTOTHECIN; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; DNA DAMAGE; ENDOTHELIN-1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MULTIPROTEIN COMPLEXES; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887425775     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.395     Document Type: Article

References (58)

1. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009; 15: 7582-7592
2. Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 2011; 104: 399-406
3. Rini BI. New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010; 16: 1348-1354
4. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000
5. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231-1241
6. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1: 237-246
7. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1: 247-255
8. Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23: 18-25
9. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264-6270
10. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686
11. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003; 63: 6130-6134
12. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov 2011; 1: 222-235
13. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 2009; 106: 14391-14396
14. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 2009; 69: 9056-9064
15. Tomicic MT, Kaina B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta 2013; 1835: 11-27
16. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res 2011; 17: 5123-5131
17. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004; 3: 172-175
18. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62: 4316-4324
19. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Res 2004; 64: 1475-1482
20. Semenza GL. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-214
21. Lou JJ, Chua YL, Chew EH, Gao J, Bushell M, Hagen T. Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One 2010; 5: E10522
22. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001; 61: 6669-6673
23. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 2005; 19: 342-353
24. Galban S, Martindale JL, Mazan-Mamczarz K, Lopez De Silanes I, Fan J, Wang W et al. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol 2003; 23: 7083-7095
25. Roe JS, Youn HD. The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle 2006; 5: 2054-2056
26. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22: 395-405
27. Carroll VA, Ashcroft M. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res 2008; 68: 545-552
28. Kunz C, Pebler S, Otte J, von Der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res 1995; 23: 3710-3717
29. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000; 19: 6297-6305
30. Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: Initiators of the cellular genotoxic stress responses. Carcinogenesis 2003; 24: 1571-1580
31. Nayak BK, Feliers D, Sudarshan S, Friedrichs WE, Day RT, New DD et al. Stabilization of HIF-2alpha through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene 2012; 32: 3147-3155
32. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008; 283: 34495-34499
33. Maru S, Ishigaki Y, Shinohara N, Takata T, Tomosugi N, Nonomura K. Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2alpha expression in human renal cell carcinoma. J Urol 2013; 189: 1921-1929
34. Law TM, Ilson DH, Motzer RJ. Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 1994; 12: 143-145
35. Fizazi K, Rolland F, Chevreau C, Droz JP, Mery-Mignard D, Culine S et al. A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 2003; 98: 61-65
36. Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA et al. First-inhuman phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013; 31: 986-1000
37. Stickle NH, Cheng LS, Watson IR, Alon N, Malkin D, Irwin MS et al. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat Res 2005; 578: 23-32
38. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9: 724-737
39. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011; 192: 547-556
40. Coppe JP, Kauser K, Campisi J, Beausejour CM. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 2006; 281: 29568-29574
41. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 2006; 8: 877-884
42. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24: 2463-2479
43. Minamino T, Komuro I. Vascular cell senescence: Contribution to atherosclerosis. Circ Res 2007; 100: 15-26
44. Hyter S, Coleman DJ, Ganguli-Indra G, Merrill GF, Ma S, Yanagisawa M et al. Endothelin-1 is a transcriptional target of p53 in epidermal keratinocytes and regulates ultraviolet-induced melanocyte homeostasis. Pigment Cell Melanoma Res 2013; 26: 247-258
45. Stow LR, Jacobs ME, Wingo CS, Cain BD. Endothelin-1 gene regulation. FASEB J 2011; 25: 16-28
46. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008; 86: 485-498
47. Kedzierski RM, Yanagisawa M. Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851-876
48. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006; 111: 508-531
49. Pflug BR, Zheng H, Udan MS, DAntonio JM, Marshall FF, Brooks JD et al. Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 2007; 246: 139-148
50. Groenewegen G, Walraven M, Vermaat J, De Gast B, Witteveen E, Giles R et al. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer 2012; 106: 284-289
51. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35
52. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20: 427-434
53. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102: 8204-8209
54. Lee CH, Inoki K, Karbowniczek M, Petroulakis E, Sonenberg N, Henske EP et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J 2007; 26: 4812-4823
55. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275
56. Valentine JM, Kumar S, Moumen AA. p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer 2011; 11: 79
57. Yang J, Ahmed A, Poon E, Perusinghe N, De Haven Brandon A, Box G et al. Smallmolecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009; 29: 2243-2253
58. Kumar A, Kim CS, Hoffman TA, Naqvi A, Dericco J, Jung SB et al. p53 impairs endothelial function by transcriptionally repressing Kruppel-Like Factor 2. Arterioscler Thromb Vasc Biol 2011; 31: 133-141